Articles from Rafael Holdings, Inc.

Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™

Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need

Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential

Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments

Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments

Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities

Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 million

Announces expanded search for strategic opportunities beyond biopharma

NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSERFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023.

NEWARK, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSERFL), today reported its first quarter fiscal 2023 financial results for the three months ended October 31, 2022.

NEWARK, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSERFL) today announced its decision to curtail its early-stage development efforts, including pre-clinical research at the Barer Institute in order to reduce spending and focus on exploring strategic opportunities to invest in, acquire, or in-license clinical stage assets.

NEWARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSERFL), a holding company with interests in clinical and early-stage pharmaceutical companies, today reported its financial results for the three and twelve months ended July 31, 2022. The Company is accelerating its focus on exploring strategic opportunities to further enhance value while continuing to develop and evaluate its pipeline.